Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
about
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the ImplicationsFunds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of NaplesEstablishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
P2860
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
Managed Entry Agreements for O ...... xperience to Inform the Future
@ast
Managed Entry Agreements for O ...... xperience to Inform the Future
@en
type
label
Managed Entry Agreements for O ...... xperience to Inform the Future
@ast
Managed Entry Agreements for O ...... xperience to Inform the Future
@en
prefLabel
Managed Entry Agreements for O ...... xperience to Inform the Future
@ast
Managed Entry Agreements for O ...... xperience to Inform the Future
@en
P2860
P50
P356
P1476
Managed Entry Agreements for O ...... xperience to Inform the Future
@en
P2093
Kim Pauwels
Sabine Vogler
P2860
P356
10.3389/FPHAR.2017.00171
P577
2017-04-04T00:00:00Z